Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficacy
- Â Uncovering the current status and unmet medical needs for patients with RAS-driven cancers, what cancers need more improved response rates?
- What genomic features predict poor response and outcomes for RAS-targeting therapies?
- How do you successfully overcome or delay resistance to RAS-targeting therapies?